GURUFOCUS.COM » STOCK LIST » USA » NAS » Atara Biotherapeutics Inc (NAS:ATRA) » Definitions » ROE %
Switch to:

Atara Biotherapeutics ROE %

: -139.87% (As of Mar. 2022)
View and export this data going back to 2014. Start your Free Trial

ROE % is calculated as Net Income attributable to Common Stockholders (Net Income minus dividends to participating security holders) divided by its average Total Stockholders Equity over a certain period of time. Atara Biotherapeutics's annualized net income attributable to common stockholders for the quarter that ended in Mar. 2022 was $-352.42 Mil. Atara Biotherapeutics's average Total Stockholders Equity over the quarter that ended in Mar. 2022 was $251.97 Mil. Therefore, Atara Biotherapeutics's annualized ROE % for the quarter that ended in Mar. 2022 was -139.87%.

The historical rank and industry rank for Atara Biotherapeutics's ROE % or its related term are showing as below:

ATRA' s ROE % Range Over the Past 10 Years
Min: -113.27   Med: -71.1   Max: -27.36
Current: -113.27

During the past 10 years, Atara Biotherapeutics's highest ROE % was -27.36%. The lowest was -113.27%. And the median was -71.10%.

ATRA's ROE % is ranked worse than
83.81% of 1439 companies
in the Biotechnology industry
Industry Median: -38.43 vs ATRA: -113.27

Atara Biotherapeutics ROE % Historical Data

The historical data trend for Atara Biotherapeutics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
ROE %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -55.37 -89.29 -92.43 -81.43 -91.69

Atara Biotherapeutics Quarterly Data
Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
ROE % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -72.75 -91.76 -105.55 -126.63 -139.87

Competitive Comparison

For the Biotechnology subindustry, Atara Biotherapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Atara Biotherapeutics ROE % Distribution

For the Biotechnology industry and Healthcare sector, Atara Biotherapeutics's ROE % distribution charts can be found below:

* The bar in red indicates where Atara Biotherapeutics's ROE % falls into.



Atara Biotherapeutics ROE % Calculation

Atara Biotherapeutics's annualized ROE % for the fiscal year that ended in Dec. 2021 is calculated as

ROE %=Net Income attributable to Common Stockholders (A: Dec. 2021 )/( (Total Stockholders Equity (A: Dec. 2020 )+Total Stockholders Equity (A: Dec. 2021 ))/ count )
=-340.141/( (462.339+279.614)/ 2 )
=-340.141/370.9765
=-91.69 %

Atara Biotherapeutics's annualized ROE % for the quarter that ended in Mar. 2022 is calculated as

ROE %=Net Income attributable to Common Stockholders (Q: Mar. 2022 )/( (Total Stockholders Equity (Q: Dec. 2021 )+Total Stockholders Equity (Q: Mar. 2022 ))/ count )
=-352.42/( (279.614+224.316)/ 2 )
=-352.42/251.965
=-139.87 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income attributable to common stockholders of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. ROE % is displayed in the 30-year financial page.


Atara Biotherapeutics  (NAS:ATRA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %**(Q: Mar. 2022 )
=Net Income/Total Stockholders Equity
=-352.42/251.965
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-352.42 / 29.256)*(29.256 / 432.7035)*(432.7035 / 251.965)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1204.61 %*0.0676*1.7173
=ROA %*Equity Multiplier
=-81.43 %*1.7173
=-139.87 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %**(Q: Mar. 2022 )
=Net Income/Total Stockholders Equity
=-352.42/251.965
=(Net Income /Pre-Tax Income) * (Pre-Tax Income/Operating Income) * (Operating Income/Revenue) * (Revenue/Total Assets) * (Total Assets/Total Stockholders Equity)
= (-352.42 / -352.42) * (-352.42 / -352.88) * (-352.88 / 29.256) * (29.256 / 432.7035) * (432.7035 / 251.965)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9987 * -1206.18 % * 0.0676 * 1.7173
=-139.87 %

Note: The net income attributable to common stockholders data used here is four times the quarterly (Mar. 2022) net income attributable to common stockholders data. The Revenue data used here is four times the quarterly (Mar. 2022) revenue data. The same rule applies to Pre-Tax Income and Operating Income.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.


Be Aware

Net income attributable to common stockholders is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Atara Biotherapeutics ROE % Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Atara Biotherapeutics Business Description

Atara Biotherapeutics logo
Traded in Other Exchanges
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and CAR T Programs.
Executives
Yarema Kristin officer: Chief Commercial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD., SUITE 900 SOUTH SAN FRANCISCO CA 94080
Murugan Amar officer: SVP, GC & Secretary C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD,SUITE 900 SOUTH SAN FRANCISCO CA 94080
Dupont Jakob officer: EVP, Head of R&D C/O ONCOMED PHARMACEUTICALS, INC. 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063
Touchon Pascal director, officer: President and CEO C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD SUITE 900 SOUTH SAN FRANCISCO CA 94080
Koppikar Utpal officer: Chief Financial Officer C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Mallik Ameet director C/O RAFAEL HOLDINGS, INC. 520 BROAD ST NEWARK NJ 07102
Renaud Ronald C Jr director C/O IDENIX PHARMACEUTICALS, INC. 60 HAMPSHIRE STREET CAMBRIDGE MA 02109
Seidenberg Beth C director
Heiden William K director C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Dobmeier Eric director C/O SAETTLE GENETICS INC 21823 30TH DRIVE SE BOTHELL WA 98021
Roncarolo Maria Grazia director C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080
Gallagher Carol Giltner director C/O ATARA BIOTHERAPEUTICS, INC. 3260 BAYSHORE BOULEVARD BRISBANE CA 94005
Fust Matthew K director C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Baynes Roy D. director C/O RETROPHIN, INC. 12255 EL CAMINO REAL, SUITE 250 SAN DIEGO CA 92130
Berger Dietmar officer: Global Head of R&D C/O ATARA BIOTHERAPEUTICS, INC. 611 GATEWAY BOULEVARD, SUITE 900 SOUTH SAN FRANCISCO CA 94080

Atara Biotherapeutics Headlines

Other Sources

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)